Somewhat Positive News Coverage Somewhat Unlikely to Impact Celsion (CLSN) Stock Price
News headlines about Celsion (NASDAQ:CLSN) have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celsion earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.4546405238643 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Celsion (NASDAQ CLSN) opened at $2.68 on Friday. Celsion has a 52-week low of $1.24 and a 52-week high of $8.82. The company has a market capitalization of $44.65, a P/E ratio of -0.46 and a beta of 1.22.
CLSN has been the subject of several recent analyst reports. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, October 4th. Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Oppenheimer started coverage on Celsion in a research note on Tuesday, November 21st. They set an “outperform” rating and a $9.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $11.90.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.